CRA consultants supported a pharmaceutical company in its successful challenge of an ANDA filed by a generic manufacturer. The generic company sought to manufacture and sell generic versions of two related diabetes treatments. CRA provided a report analyzing evidence of commercial success for the branded pharmaceutical products as well as deposition and trial testimony.
IP Literature Watch: April 2024
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on IP & antitrust, licensing, litigation, innovation, law...